Form 4: Director Saira Ramasastry Executes MIRM Stock Options

Mirum Pharmaceuticals director Saira Ramasastry exercised 2,000 stock options and subsequently sold the shares.

Summary

• Director Saira Ramasastry exercised 2,000 stock options at a strike price of $23.51 per share.
• Following the exercise, the director sold all 2,000 shares at a price of $96.90 per share.
• The transactions were executed on April 15, 2026, pursuant to a Rule 10b5-1 trading plan adopted on September 18, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents standard portfolio management by a director.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sale was not based on non-public information.

Negatives

• The director reduced their direct beneficial ownership of common stock to zero following the sale.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via pre-arranged 10b5-1 plans is standard corporate practice and generally does not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for directors to liquidate equity positions while maintaining compliance with SEC insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was executed via a pre-established plan.

Key Dates

Keywords

MIRM, Mirum Pharmaceuticals, Insider Trading, Form 4, Stock Options, Director Transaction